KTTA
Pasithea Therapeutics Corp.
Biotechnology
Market Cap$19M
5Y Perf.-98.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KTTA vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-96.7%
KTTA vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KTTA | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $19M | $85M |
| Revenue (TTM) | $0.00 | $242K |
| Net Income (TTM) | $-13M | $-38M |
| Gross Margin | — | 59.5% |
| Operating Margin | — | -63.0% |
| Total Debt | $0.00 | $631K |
| Cash & Equiv. | $7M | $8M |
KTTA vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KTTA
NRXP
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Pasithea Therapeuti… (KTTA) | 100 | 1.4 | -98.6% |
| NRx Pharmaceuticals… (NRXP) | 100 | 3.3 | -96.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KTTA vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KTTA leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KTTA
Pasithea Therapeutics Corp.
The Income Pick
KTTA carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.92
- Lower volatility, beta 0.92, current ratio 6.58x
- Beta 0.92, current ratio 6.58x
Best for: income & stability and sleep-well-at-night
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 43.9%
- -96.8% 10Y total return vs KTTA's -98.8%
- 101.1% revenue growth vs KTTA's 15.2%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs KTTA's 15.2% |
| Quality / Margins | KTTA | 2.6% margin vs NRXP's -157.3% |
| Stability / Safety | KTTA | Beta 0.92 vs NRXP's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NRXP | +55.3% vs KTTA's -25.7% |
| Efficiency (ROA) | KTTA | -88.0% ROA vs NRXP's -489.9% |
KTTA vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KTTA vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNRXPLAGGINGKTTA
KTTAPasithea Therapeutics…
1leads
NRXPNRx Pharmaceuticals, …
2leads
6 Total Categories
CATEGORYLEADERvs KTTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KTTA1/1
Valuation MetricsMultiples, price ratios, and targets
NRXP1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
NRXP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KTTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NRXP and KTTA operate at a comparable scale, with $242,000 and $0 in trailing revenue.
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $242,000 |
| EBITDAEarnings before interest/tax | -$13M | -$31M |
| Net IncomeAfter-tax profit | -$13M | -$38M |
| Free Cash FlowCash after capex | -$12M | -$12M |
| Gross MarginGross profit ÷ Revenue | — | +59.5% |
| Operating MarginEBIT ÷ Revenue | — | -63.0% |
| Net MarginNet income ÷ Revenue | — | -157.3% |
| FCF MarginFCF ÷ Revenue | — | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +85.7% | -80.0% |
KTTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NRXP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $19M | $85M |
| Enterprise ValueMkt cap + debt − cash | $12M | $78M |
| Trailing P/EPrice ÷ TTM EPS | -0.07x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 69.15x |
| Price / BookPrice ÷ Book value/share | 0.06x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
NRXP leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — KTTA and NRXP each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs KTTA's 2/9, reflecting solid financial health.
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -97.9% | — |
| ROA (TTM)Return on assets | -88.0% | -4.9% |
| ROICReturn on invested capital | -142.4% | — |
| ROCEReturn on capital employed | -74.2% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$7M | -$7M |
| Cash & Equiv.Liquid assets | $7M | $8M |
| Total DebtShort + long-term debt | $0 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -24.18x |
Evenly matched — KTTA and NRXP each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
NRXP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KTTA five years ago would be worth $118 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, NRXP leads with a +55.3% total return vs KTTA's -25.7%. The 3-year compound annual growth rate (CAGR) favors NRXP at -21.0% vs KTTA's -50.9% — a key indicator of consistent wealth creation.
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | -29.4% | +16.8% |
| 1-Year ReturnPast 12 months | -25.7% | +55.3% |
| 3-Year ReturnCumulative with dividends | -88.2% | -50.6% |
| 5-Year ReturnCumulative with dividends | -98.8% | -99.1% |
| 10-Year ReturnCumulative with dividends | -98.8% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -50.9% | -21.0% |
NRXP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KTTA and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
KTTA is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than NRXP's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs KTTA's 40.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.92x | 1.91x |
| 52-Week HighHighest price in past year | $2.06 | $3.84 |
| 52-Week LowLowest price in past year | $0.28 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +40.8% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 63.4 | 64.7 |
| Avg Volume (50D)Average daily shares traded | 457K | 913K |
Evenly matched — KTTA and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KTTAPasithea Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NRXP leads in 2 of 6 categories (Valuation Metrics, Total Returns). KTTA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallNRx Pharmaceuticals, Inc. (NRXP)Leads 2 of 6 categories
Loading custom metrics...
KTTA vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — KTTA or NRXP?
Over the past 5 years, Pasithea Therapeutics Corp.
(KTTA) delivered a total return of -98. 8%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: NRXP returned -96. 8% versus KTTA's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — KTTA or NRXP?
By beta (market sensitivity over 5 years), Pasithea Therapeutics Corp.
(KTTA) is the lower-risk stock at 0. 92β versus NRx Pharmaceuticals, Inc. 's 1. 91β — meaning NRXP is approximately 107% more volatile than KTTA relative to the S&P 500.
03Which is growing faster — KTTA or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to 2. 5% for Pasithea Therapeutics Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — KTTA or NRXP?
Pasithea Therapeutics Corp.
(KTTA) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KTTA leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KTTA or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KTTA or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Pasithea Therapeutics Corp.
(KTTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KTTA: -98. 8%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KTTA and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.